RecruitingNCT06436846

Genomic Risk in Retroperitoneal Sarcoma

Characterization of the Genomic Risk Underlying Retroperitoneal Liposarcoma

Sponsor

Fox Chase Cancer Center

Enrollment

50 participants

Start Date

Mar 7, 2022

Study Type

OBSERVATIONAL

Conditions

Soft Tissue Sarcoma Retroperitoneal Liposarcoma

Summary

The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines the genetic makeup of retroperitoneal liposarcoma — a rare cancer that grows in the fat tissue behind the abdominal organs — to better predict how likely the cancer is to come back after surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with retroperitoneal liposarcoma (confirmed by biopsy or imaging) - You are scheduled for surgical removal of your tumor (whether it is a new or recurring case) - You are willing and able to provide informed consent **You may NOT be eligible if...** - You have had prior surgery that makes it technically impossible or unsafe to take tissue samples from the affected area Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiospecimen sample collection during standard-of-care surgery

Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.

Locations(1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06436846

Related Trials

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

NCT052649741 location

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

NCT072436261 location

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

NCT0571269431 locations

Pre-operative Hypofractionated Proton Therapy

NCT059173011 location

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

NCT045770141 location